1 February 2024
Tekcapital Plc
("Tekcapital", the "Company" or "the Group")
MicroSalt® Admission to AIM and First Day of Dealings
Tekcapital Plc (AIM: TEK) the UK intellectual property investment group focused on creating valuable products that can improve people's lives, is delighted to announce that MicroSalt® plc ("Microsalt") ordinary shares have been admitted to trading on the AIM market of the London Stock Exchange plc ("Admission") and dealings in the Ordinary Shares have commenced at 8.00 a.m. today, 1 February 2024, under the ticker SALT.
Admission highlights
· Market capitalisation of approximately £18.5 million on Admission.
· Successful fundraise totalling approximately £3.14 million (before expenses).
· Tekcapital holds a 77.24% interest in MicroSalt, which at the listing price of 43p per ordinary share, is valued at approximately £14.3m on Admission.
Rick Guiney, CEO of MicroSalt, said:
"We are delighted to announce our successful fundraise and admission to AIM, which is an important step in our development and provides an excellent platform for future growth. The World Health Organisation has stated ambitions to reduce sodium intake by 30% by 2025, and MicroSalt is extremely well placed to help meet the rising demand for lower sodium products with our disruptive, proprietary product and manufacturing process."
According to the WHO[1], "Implementing highly cost-effective sodium reduction policies could save an estimated 7 million lives globally by 2030."
Dr Clifford Gross, CEO of Tekcapital, said:
"Tekcapital's mission is to commercialise new technologies that can improve the quality of life of the customers we serve. MicroSalt has established a new category of full-flavour, low sodium salt, and has demonstrated initial success in onboarding two major B2B companies to incorporate MicroSalt into their existing products and has placed its saltshakers and crisps in hundreds of stores. It's become clear to us, that up until now, there hasn't been a food ingredient that could accomplish sodium reduction without sacrificing flavour. That has now changed. We're excited that MicroSalt has completed its IPO and we are looking forward to their future growth and success. "
Tekcapital holds 33,305,749 ordinary shares of MicroSalt plc which are subject to a 12-month lock-in period from the date of admission. This includes 2,588,140 new ordinary shares which Tekcapital subscribed for in the fundraising at the listing price. Additionally, Tekcapital holds approximately 2.6m warrants exercisable for a period of three years from the date of Admission at 10% above the IPO price.
About MicroSalt® plc
MicroSalt, is the developer and manufacturer of a proprietary low-sodium salt called MicroSalt®. We are passionate about improving peoples' lives with better-for-you seasonings and snacks by taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavour because it is salt. Our new patented technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption. Additionally, the ultra-small particle size enhances product adhesion, which reduces waste and provides improved flavour consistency. MicroSalt® and SaltMe® are registered trademarks of MicroSalt Inc.
To learn more about MicroSalt please visit https://www.microsalt.co
Zeus Capital acted as Nominated Adviser and sole Broker to MicroSalt and SP Angel Corporate Finance LLP served as placement sub-agent.
About Tekcapital plc
Tekcapital creates value from investing in new, university-developed discoveries that can enhance people's lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.
LEI: 213800GOJTOV19FIFZ85
For further information, please contact:
Tekcapital Plc |
|
Via Flagstaff IR |
Clifford M. Gross, Ph.D. |
|
|
|
|
|
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) |
|
+44 (0) 20 3470 0470 |
Richard Morrison / Charlie Bouverat (Corporate Finance) Rob Rees (Corporate Broking)
|
|
|
Flagstaff Strategic and Investor Communications +44 (0)207 129 1474
Tim Thompson/Andrea Seymour/Fergus Mellon
tekcapital@flagstaffcomms.com
This press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving MicroSalt that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of MicroSalt's and/or Tekcapital's management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of MicroSalt or Tekcapital may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Neither MicroSalt nor Tekcapital intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.